Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.

Mega, Jessica L

Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. [electronic resource] - Lancet (London, England) Oct 2010 - 1312-9 p. digital

Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

1474-547X

10.1016/S0140-6736(10)61273-1 doi


ATP Binding Cassette Transporter, Subfamily B
ATP Binding Cassette Transporter, Subfamily B, Member 1--genetics
Acute Coronary Syndrome--drug therapy
Angioplasty, Balloon, Coronary
Aryl Hydrocarbon Hydroxylases--genetics
Cardiovascular Diseases--etiology
Clopidogrel
Cytochrome P-450 CYP2C19
Female
Genetic Variation
Genotype
Humans
Male
Middle Aged
Pharmacogenetics
Piperazines--adverse effects
Platelet Aggregation--drug effects
Platelet Aggregation Inhibitors--adverse effects
Polymorphism, Single Nucleotide
Prasugrel Hydrochloride
Randomized Controlled Trials as Topic
Thiophenes--adverse effects
Ticlopidine--adverse effects